WallStSmart
NNNN

Anbio Biotechnology Class A Ordinary Shares

NASDAQ: NNNN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$27.43
-1.37% today

Updated 2026-04-29

Market cap
$1.20B
P/E ratio
182.87
P/S ratio
139.23x
EPS (TTM)
$0.15
Dividend yield
52W range
$6 – $56
Volume
0.0M

WallStSmart proprietary scores

52
out of 100
Grade: C
Hold
Investment rating
5.3
Growth
C+
6.5
Quality
B
9.5
Profitability
A+
4.0
Valuation
C
4/9
Piotroski F-Score
Moderate
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$—
12-Month target
$0.68
-97.52%
Intrinsic (DCF)
Margin of safety

Price chart

X-Ray snapshot

Strengths
+ Profit margin 74.10% — above average
+ ROE 27.10% — strong efficiency
+ Revenue growth 73.90% QoQ
Risks
- Negative free cash flow $-6.74M
- P/E 182.87x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$23.54M$6.71M$8.19M$8.65M$8.65M
Net income$10.01M$2.25M$2.37M$6.40M$3.04M
EPS$0.15
Free cash flow$4.45M$898367.00$2.08M$-6.74M$-6.74M
Profit margin42.52%33.58%28.99%74.06%74.10%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
NNNN$1.20B525.39.54.06.5Buy
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Anbio Biotechnology Class A Ordinary Shares trades at $27.43. representing a P/E of 182.87x trailing earnings. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $8.65M. with profit margins at 74.10%.

Frequently asked questions

What is Anbio Biotechnology Class A Ordinary Shares's stock price?
Anbio Biotechnology Class A Ordinary Shares (NNNN) trades at $27.43.
Is Anbio Biotechnology Class A Ordinary Shares overvalued?
Smart Value Score 52/100 (Grade C, Hold).
What is the price target of Anbio Biotechnology Class A Ordinary Shares (NNNN)?
The analyst target price is $—, representing NaN% downside from the current price of $27.43.
What is Anbio Biotechnology Class A Ordinary Shares's revenue?
TTM revenue is $8.65M.
Piotroski F-Score?
4/9 — moderate financial health.

Company info

SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio139.23x
ROE27.10%
Beta
50D MA$25.00
200D MA$31.90
Shares out0.04B
Float0.04B
Short ratio
Avg volume0.0M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years